Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

Pharmaceutical

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals' headquarters in Coral Gables, FL, United States

Patrick J. McEnany 

Michael Kalb

Mary Coleman

Gary Ingenito

Jeff Del Carmen

Preethi Sundaram

Steven R. Miller

Alicia Grande

Brian Elsbernd

Richard J. Daly

Charles B. O’Keeffe

David S. Tierney

Donald A. Denkhaus

Tamar Thompson

Philip H. Coelho

Molly Harper

Description

People (10)

David Cruz

Justin T.

Julian Serna

Diana Gabe

Jacqueline Gatto

Tara Bey

John Collar

Pete Curry

Ylse Martinez

Mark Hardison Cpim-F

Jobs